Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R R Redfield

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
The Journal of Infectious Diseases|February 1, 1997
Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgGG H Lowell, R W Kaminski, T C VanCott, et al.
Human Gene Therapy|December 1, 1994
Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cellsJ H Kim, S Ratto, K V Sitz, et al.
Journal of Acquired Immune Deficiency Syndromes|January 11, 1992
Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied RetrovirologyL I Gardner, J F Brundage, J G McNeil, et al.
Science (New York, N.Y.)|June 20, 1986
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDSB H Hahn, G M Shaw, M E Taylor, et al.
Journal of the American Academy of Dermatology|October 1, 1985
A papular eruption associated with human T cell lymphotropic virus type III diseaseW D James, R R Redfield, G P Lupton, et al.
Clinical and Experimental Immunology|May 1, 1997
Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: IL-7 and IL-12 differentially augment cellular proliferative responses to HIV-1J H Kim, J E Loveland, K V Sitz, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 5, 2016
Does DCD Donor Time-to-Death Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United StatesJ R Scalea, R R Redfield, E Arpali, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
The Journal of Infectious Diseases|March 18, 2000
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine InvestigatorsD L Birx, L D Loomis-Price, N Aronson, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
The Journal of Infectious Diseases|February 1, 1997
Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgGG H Lowell, R W Kaminski, T C VanCott, et al.
Human Gene Therapy|December 1, 1994
Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cellsJ H Kim, S Ratto, K V Sitz, et al.
Journal of Acquired Immune Deficiency Syndromes|January 11, 1992
Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied RetrovirologyL I Gardner, J F Brundage, J G McNeil, et al.
Science (New York, N.Y.)|June 20, 1986
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDSB H Hahn, G M Shaw, M E Taylor, et al.
Journal of the American Academy of Dermatology|October 1, 1985
A papular eruption associated with human T cell lymphotropic virus type III diseaseW D James, R R Redfield, G P Lupton, et al.
Clinical and Experimental Immunology|May 1, 1997
Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: IL-7 and IL-12 differentially augment cellular proliferative responses to HIV-1J H Kim, J E Loveland, K V Sitz, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 5, 2016
Does DCD Donor Time-to-Death Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United StatesJ R Scalea, R R Redfield, E Arpali, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
The Journal of Infectious Diseases|March 18, 2000
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine InvestigatorsD L Birx, L D Loomis-Price, N Aronson, et al.
Pageof 11